178 related articles for article (PubMed ID: 25700621)
1. Clinical safety, tolerability, pharmacokinetics and pharmacodynamics of the novel factor Xa inhibitor DY-807f in healthy volunteers.
Ogata K; Shimizu T; Masumoto H; Oguma T; Sugiyama N; Kunitada S
Thromb Res; 2015 Apr; 135(4):594-601. PubMed ID: 25700621
[TBL] [Abstract][Full Text] [Related]
2. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
[TBL] [Abstract][Full Text] [Related]
3. Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
Schmitt C; Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
J Clin Pharmacol; 2012 Apr; 52(4):499-510. PubMed ID: 21566199
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
Kubitza D; Becka M; Voith B; Zuehlsdorf M; Wensing G
Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
[TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects.
Xuan D; McBride S; Wastall P; Porcari A; DiCarlo L; Boyd RA
Clin Pharmacol Drug Dev; 2016 Jan; 5(1):13-26. PubMed ID: 27119575
[TBL] [Abstract][Full Text] [Related]
6. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
Frost C; Wang J; Nepal S; Schuster A; Barrett YC; Mosqueda-Garcia R; Reeves RA; LaCreta F
Br J Clin Pharmacol; 2013 Feb; 75(2):476-87. PubMed ID: 22759198
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, pharmacodynamics and food effect of LB30870, a novel direct thrombin inhibitor, after single oral doses in healthy men.
Kim J; Lee SH; Boyce M; Warrington S; Cho KH; Yoon SK; Park HD; Kim A
Xenobiotica; 2015; 45(8):663-71. PubMed ID: 25673087
[TBL] [Abstract][Full Text] [Related]
9. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
10. Dose-finding study of rivaroxaban in hemodialysis patients.
De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic evaluation of oral rivaroxaban in healthy adult cats.
Dixon-Jimenez AC; Brainard BM; Brooks MB; Nie B; Arnold RD; Loper D; Abrams JC; Rapoport GS
J Vet Emerg Crit Care (San Antonio); 2016 Sep; 26(5):619-29. PubMed ID: 27599304
[TBL] [Abstract][Full Text] [Related]
12. First in man study of EP217609, a new long-acting, neutralisable parenteral antithrombotic with a dual mechanism of action.
Gueret P; Combe S; Krezel C; Fuseau E; van Giersbergen PL; Petitou M; Neuhart E
Eur J Clin Pharmacol; 2016 Sep; 72(9):1041-50. PubMed ID: 27259709
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXa
Parsons-Rich D; Hua F; Li G; Kantaridis C; Pittman DD; Arkin S
J Thromb Haemost; 2017 May; 15(5):931-937. PubMed ID: 28294526
[TBL] [Abstract][Full Text] [Related]
14. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Barrett YC; Wang Z; Frost C; Shenker A
Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of R1663, an oral factor Xa inhibitor, in healthy young subjects coupled with exploration of influence of gender and age.
Schmitt C; Charoin-Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
Thromb Haemost; 2012 Jul; 108(1):54-64. PubMed ID: 22552265
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects.
Kadokura T; Kashiwa M; Groenendaal D; Heeringa M; Mol R; Verheggen F; Garcia-Hernandez A; Onkels H
Biopharm Drug Dispos; 2013 Nov; 34(8):431-41. PubMed ID: 23929659
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa.
Graefe-Mody EU; Schühly U; Rathgen K; Stähle H; Leitner JM; Jilma B
J Thromb Haemost; 2006 Jul; 4(7):1502-9. PubMed ID: 16839346
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
Barbier AJ; Hilhorst M; Van Vliet A; Snyder P; Palfreyman MG; Gawryl M; Dgetluck N; Massaro M; Tiessen R; Timmerman W; Hilt DC
Clin Ther; 2015 Feb; 37(2):311-24. PubMed ID: 25438724
[TBL] [Abstract][Full Text] [Related]
19. Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration.
Frost C; Garonzik S; Shenker A; Barrett YC; LaCreta F
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):974-984. PubMed ID: 34342172
[TBL] [Abstract][Full Text] [Related]
20. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.
Kubitza D; Becka M; Wensing G; Voith B; Zuehlsdorf M
Eur J Clin Pharmacol; 2005 Dec; 61(12):873-80. PubMed ID: 16328318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
